Source: Sharecast
Physiomics said the project will use PK/PD modelling and simulation approaches to inform understanding and selection of appropriate clinical dosing for a first-in-human study for an antibody in Numab's inflammation pipeline.
The AIM-listed group said work for the project was expected to begin "imminently" and was expected to be completed within the next six months.
Physiomics added that the project represents "another important step" in its ongoing collaboration applying model-informed drug development to support a data-driven approach to drug development and, in this case, first-in-human dose selection.
Chief executive Dr Peter Sargent said: "We're delighted to be deepening our existing relationship with Numab Therapeutics through this new project. Applying our MIDD expertise to support early clinical development aligns perfectly with our mission to help clients make smarter, faster decisions that can help de-risk development and improve outcomes."
As of 1055 BST, Physiomics shares were up 1.51% at 0.47p.
Reporting by Iain Gilbert at Sharecast.com